Barclays PLC Vertex Pharmaceuticals Inc Put Options Transaction History

Barclays PLC

$377 Billion
Q3 2024

Put Options

22 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 15, 2024	BUY	$460.0 - $505.78 $10.1 Million - $11.1 Million	21,900 New	21,900 $10.2 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $5.63 Million - $6.16 Million	13,800 Added 38.33%	49,800 $20.8 Million
Q4 2023 Feb 15, 2024	BUY	$343.0 - $410.68 $4.6 Million - $5.5 Million	13,400 Added 59.29%	36,000 $14.6 Million
Q3 2023 Nov 07, 2023	BUY	$338.18 - $362.46 $7.64 Million - $8.19 Million	22,600 New	22,600 $7.86 Million
Q3 2022 Nov 03, 2022	SELL	$273.83 - $305.53 $20.2 Million - $22.5 Million	-73,800 Reduced 69.1%	33,000 $9.55 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $14.2 Million - $17.7 Million	-60,600 Reduced 36.2%	106,800 $30.1 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $25.2 Million - $31.8 Million	142,400 Added 569.6%	167,400 $36.8 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $4.57 Million - $5.39 Million	24,400 Added 4066.67%	25,000 $5.04 Million
Q1 2021 May 13, 2021	SELL	$207.02 - $241.31 $11.3 Million - $13.1 Million	-54,400 Reduced 98.91%	600 $128,000
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $153,390 - $181,860	600 Added 1.1%	55,000 $15 Million
Q2 2020 Aug 12, 2020	SELL	$225.48 - $295.8 $3.07 Million - $4.02 Million	-13,600 Reduced 20.0%	54,400 $15.8 Million
Q1 2020 May 13, 2020	SELL	$199.77 - $247.81 $679,218 - $842,554	-3,400 Reduced 4.76%	68,000 $16.2 Million
Q4 2019 Feb 10, 2020	BUY	$166.71 - $223.91 $3.15 Million - $4.23 Million	18,900 Added 36.0%	71,400 $15.6 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $3.56 Million - $4 Million	21,400 Added 68.81%	52,500 $8.9 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $13 Million - $15 Million	-78,700 Reduced 71.68%	31,100 $5.7 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $1.29 Million - $1.54 Million	-7,900 Reduced 6.71%	109,800 $20.2 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $10 Million - $12.7 Million	-65,900 Reduced 35.89%	117,700 $19.5 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $20.9 Million - $24 Million	124,600 Added 211.19%	183,600 $35.4 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $1.22 Million - $1.43 Million	8,400 Added 16.6%	59,000 $10 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $1.14 Million - $1.33 Million	-7,500 Reduced 12.91%	50,600 $8.25 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $3.62 Million - $4.11 Million	-26,400 Reduced 31.24%	58,100 $8.71 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $12.5 Million - $13.7 Million	84,500	84,500 $12.8 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.1 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.4 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.61 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.33 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.06 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account